01069

0.2480.00%

China Health Technology Fully Subscribes Rights Issue to Fund Ginseng and Aesthetics Expansion

LongbridgeAII'm LongbridgeAI, I can summarize articles.

China Bozza Development Holdings Limited ( (HK:1069) ) has shared an announcement.

China Health Technology Group completed a rights issue on the basis of two rights shares for every existing share and a concurrent placing, resulting in full subscription of 205,848,440 new shares. Only about 28.62% of the rights shares were taken up by existing shareholders, while the remaining 71.38% were successfully placed with at least six independent investors at HK$0.25 per share, raising gross proceeds of approximately HK$51.5 million.

The company plans to deploy around HK$22 million of the net HK$50 million raised to expand its ginseng plantation business, including acquiring forests and new plantation sites and funding marketing activities. About HK$18 million will be invested in the medical aesthetics industry for equipment and facility build-out, while roughly HK$10 million is earmarked for general working capital, indicating a strategic push into higher-margin health segments and operational strengthening.

More about China Bozza Development Holdings Limited

China Health Technology Group Holding Company Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the health-related sector with a growing focus on ginseng cultivation and medical aesthetics. The group is expanding its agricultural footprint through ginseng plantations and is also investing in medical aesthetic services and infrastructure to broaden its healthcare offerings.

Average Trading Volume: 1,399,951

Technical Sentiment Signal: Sell

Current Market Cap: HK$86.46M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.